{"id":"https://openalex.org/W4385698347","doi":"https://doi.org/10.3389/fimmu.2023.1213920","title":"Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation","display_name":"Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation","publication_year":2023,"publication_date":"2023-08-09","ids":{"openalex":"https://openalex.org/W4385698347","doi":"https://doi.org/10.3389/fimmu.2023.1213920","pmid":"https://pubmed.ncbi.nlm.nih.gov/37622108","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/10446491"},"language":"en","primary_location":{"id":"doi:10.3389/fimmu.2023.1213920","doi":"https://doi.org/10.3389/fimmu.2023.1213920","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fimmu.2023.1213920","pdf_url":"https://www.frontiersin.org/articles/10.3389/fimmu.2023.1213920/pdf","source":{"id":"https://openalex.org/S2595292759","display_name":"Frontiers in Immunology","issn_l":"1664-3224","issn":["1664-3224"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Immunology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/articles/10.3389/fimmu.2023.1213920/pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Guo-Qing Tang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127098","display_name":"UCB Pharma (United States)","ror":"https://ror.org/028qka468","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127098","https://openalex.org/I85722119"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Guo-Qing Tang","raw_affiliation_strings":["UCB Pharma, Cambridge, MA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB Pharma, Cambridge, MA, United States","institution_ids":["https://openalex.org/I4210127098"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102433257","display_name":"Yalan Tang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127098","display_name":"UCB Pharma (United States)","ror":"https://ror.org/028qka468","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127098","https://openalex.org/I85722119"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yalan Tang","raw_affiliation_strings":["UCB Pharma, Cambridge, MA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB Pharma, Cambridge, MA, United States","institution_ids":["https://openalex.org/I4210127098"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039394135","display_name":"Ketki Dhamnaskar","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ketki Dhamnaskar","raw_affiliation_strings":["Ra Pharmaceuticals, Cambridge, MA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ra Pharmaceuticals, Cambridge, MA, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067499617","display_name":"Michelle D. Hoarty","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127098","display_name":"UCB Pharma (United States)","ror":"https://ror.org/028qka468","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127098","https://openalex.org/I85722119"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michelle D. Hoarty","raw_affiliation_strings":["UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States","institution_ids":["https://openalex.org/I4210127098"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088726722","display_name":"Rohit Vyasamneni","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rohit Vyasamneni","raw_affiliation_strings":["Ra Pharmaceuticals, Cambridge, MA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ra Pharmaceuticals, Cambridge, MA, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048832652","display_name":"Douangsone D. Vadysirisack","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127098","display_name":"UCB Pharma (United States)","ror":"https://ror.org/028qka468","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127098","https://openalex.org/I85722119"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Douangsone D. Vadysirisack","raw_affiliation_strings":["UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States","institution_ids":["https://openalex.org/I4210127098"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111665106","display_name":"Zhong Ma","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127098","display_name":"UCB Pharma (United States)","ror":"https://ror.org/028qka468","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127098","https://openalex.org/I85722119"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Zhong Ma","raw_affiliation_strings":["UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States","institution_ids":["https://openalex.org/I4210127098"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103706850","display_name":"Nanqun Zhu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127098","display_name":"UCB Pharma (United States)","ror":"https://ror.org/028qka468","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127098","https://openalex.org/I85722119"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nanqun Zhu","raw_affiliation_strings":["UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States","institution_ids":["https://openalex.org/I4210127098"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Jian-Guo Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127098","display_name":"UCB Pharma (United States)","ror":"https://ror.org/028qka468","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127098","https://openalex.org/I85722119"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jian-Guo Wang","raw_affiliation_strings":["UCB Pharma, Cambridge, MA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB Pharma, Cambridge, MA, United States","institution_ids":["https://openalex.org/I4210127098"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051124184","display_name":"Charlie Bu","orcid":"https://orcid.org/0009-0001-6888-2535","observed_orcids":["https://orcid.org/0009-0001-6888-2535"]},"institutions":[{"id":"https://openalex.org/I4210127098","display_name":"UCB Pharma (United States)","ror":"https://ror.org/028qka468","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127098","https://openalex.org/I85722119"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Charlie Bu","raw_affiliation_strings":["UCB Pharma, Cambridge, MA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB Pharma, Cambridge, MA, United States","institution_ids":["https://openalex.org/I4210127098"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101248803","display_name":"Bestine Cong","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127098","display_name":"UCB Pharma (United States)","ror":"https://ror.org/028qka468","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127098","https://openalex.org/I85722119"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bestine Cong","raw_affiliation_strings":["UCB Pharma, Cambridge, MA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB Pharma, Cambridge, MA, United States","institution_ids":["https://openalex.org/I4210127098"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Elizabeth Palmer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127098","display_name":"UCB Pharma (United States)","ror":"https://ror.org/028qka468","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127098","https://openalex.org/I85722119"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elizabeth Palmer","raw_affiliation_strings":["UCB Pharma, Cambridge, MA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB Pharma, Cambridge, MA, United States","institution_ids":["https://openalex.org/I4210127098"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113844507","display_name":"Petra W. Duda","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127098","display_name":"UCB Pharma (United States)","ror":"https://ror.org/028qka468","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127098","https://openalex.org/I85722119"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Petra W. Duda","raw_affiliation_strings":["UCB Pharma, Cambridge, MA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB Pharma, Cambridge, MA, United States","institution_ids":["https://openalex.org/I4210127098"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075377843","display_name":"Camil Elie Sayegh","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127098","display_name":"UCB Pharma (United States)","ror":"https://ror.org/028qka468","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127098","https://openalex.org/I85722119"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Camil Sayegh","raw_affiliation_strings":["UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States","institution_ids":["https://openalex.org/I4210127098"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5103777234","display_name":"Alonso Ricardo","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alonso Ricardo","raw_affiliation_strings":["Ra Pharmaceuticals, Cambridge, MA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ra Pharmaceuticals, Cambridge, MA, United States","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210127098"],"apc_list":{"value":3295,"currency":"USD","value_usd":3295},"apc_paid":{"value":3295,"currency":"USD","value_usd":3295},"fwci":5.6933,"has_fulltext":true,"cited_by_count":52,"citation_normalized_percentile":{"value":0.97270581,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":100},"biblio":{"volume":"14","issue":null,"first_page":"1213920","last_page":"1213920"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10993","display_name":"Complement system in diseases","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10993","display_name":"Complement system in diseases","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11917","display_name":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T14245","display_name":"Biomarkers in Disease Mechanisms","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/zilucoplan","display_name":"zilucoplan","score":1.0},{"id":"https://openalex.org/keywords/complement-component-5","display_name":"complement component 5","score":0.8809999823570251},{"id":"https://openalex.org/keywords/terminal-complement-pathway","display_name":"terminal complement pathway","score":0.9279999732971191},{"id":"https://openalex.org/keywords/membrane-attack-complex","display_name":"membrane attack complex","score":0.9729999899864197},{"id":"https://openalex.org/keywords/c5-convertase","display_name":"C5 convertase","score":0.7699999809265137},{"id":"https://openalex.org/keywords/macrocyclic-peptides","display_name":"macrocyclic peptides","score":0.6980000138282776},{"id":"https://openalex.org/keywords/drug-permeability","display_name":"drug permeability","score":0.6639999747276306},{"id":"https://openalex.org/keywords/basement-membrane","display_name":"basement membrane","score":0.6079999804496765},{"id":"https://openalex.org/keywords/hemolysis","display_name":"hemolysis","score":0.8569999933242798}],"concepts":[{"id":"https://openalex.org/C111684460","wikidata":"https://www.wikidata.org/wiki/Q334848","display_name":"Complement system","level":3,"score":0.8192347288131714},{"id":"https://openalex.org/C2779902561","wikidata":"https://www.wikidata.org/wiki/Q471706","display_name":"Hemolysis","level":2,"score":0.7416553497314453},{"id":"https://openalex.org/C79196540","wikidata":"https://www.wikidata.org/wiki/Q14905298","display_name":"Complement membrane attack complex","level":4,"score":0.6717519760131836},{"id":"https://openalex.org/C189446657","wikidata":"https://www.wikidata.org/wiki/Q4736500","display_name":"Alternative complement pathway","level":4,"score":0.6265442371368408},{"id":"https://openalex.org/C71318922","wikidata":"https://www.wikidata.org/wiki/Q426181","display_name":"Complement component 5","level":4,"score":0.6236976385116577},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.5712824463844299},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.5488364100456238},{"id":"https://openalex.org/C2781071845","wikidata":"https://www.wikidata.org/wiki/Q21173374","display_name":"Plasmin","level":3,"score":0.5422177910804749},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.5385000109672546},{"id":"https://openalex.org/C171279029","wikidata":"https://www.wikidata.org/wiki/Q5128320","display_name":"Classical complement pathway","level":4,"score":0.493594765663147},{"id":"https://openalex.org/C2779281246","wikidata":"https://www.wikidata.org/wiki/Q172847","display_name":"Peptide","level":2,"score":0.4382660388946533},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.4238927960395813},{"id":"https://openalex.org/C2776120743","wikidata":"https://www.wikidata.org/wiki/Q3271540","display_name":"Mechanism of action","level":3,"score":0.4153061509132385},{"id":"https://openalex.org/C12554922","wikidata":"https://www.wikidata.org/wiki/Q7100","display_name":"Biophysics","level":1,"score":0.38701409101486206},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2978687286376953},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.2907060980796814},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.24428975582122803},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003167","descriptor_name":"Complement Activation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D003167","descriptor_name":"Complement Activation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D003167","descriptor_name":"Complement Activation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D003182","descriptor_name":"Complement C5","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D003182","descriptor_name":"Complement C5","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D003182","descriptor_name":"Complement C5","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D006461","descriptor_name":"Hemolysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D006461","descriptor_name":"Hemolysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D006461","descriptor_name":"Hemolysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010456","descriptor_name":"Peptides, Cyclic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.3389/fimmu.2023.1213920","doi":"https://doi.org/10.3389/fimmu.2023.1213920","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fimmu.2023.1213920","pdf_url":"https://www.frontiersin.org/articles/10.3389/fimmu.2023.1213920/pdf","source":{"id":"https://openalex.org/S2595292759","display_name":"Frontiers in Immunology","issn_l":"1664-3224","issn":["1664-3224"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Immunology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:10446491","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10446491","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10446491/pdf/fimmu-14-1213920.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Front Immunol","raw_type":"Text"},{"id":"pmid:37622108","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/37622108","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in immunology","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:04a48afd569947a08aee94bcb0ee1d74","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/04a48afd569947a08aee94bcb0ee1d74","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Immunology, Vol 14 (2023)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.3389/fimmu.2023.1213920","doi":"https://doi.org/10.3389/fimmu.2023.1213920","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fimmu.2023.1213920","pdf_url":"https://www.frontiersin.org/articles/10.3389/fimmu.2023.1213920/pdf","source":{"id":"https://openalex.org/S2595292759","display_name":"Frontiers in Immunology","issn_l":"1664-3224","issn":["1664-3224"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Immunology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9763000011444092}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.6000000238418579}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320337846","display_name":"UCB Pharma","ror":"https://ror.org/01n029866"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4385698347.pdf","grobid_xml":"https://content.openalex.org/works/W4385698347.grobid-xml"},"referenced_works_count":34,"referenced_works":["https://openalex.org/W13194283","https://openalex.org/W315197452","https://openalex.org/W1483293311","https://openalex.org/W1572912927","https://openalex.org/W1968375523","https://openalex.org/W1984433766","https://openalex.org/W1992708993","https://openalex.org/W1995181352","https://openalex.org/W2050217807","https://openalex.org/W2100824312","https://openalex.org/W2101363963","https://openalex.org/W2113948300","https://openalex.org/W2163190168","https://openalex.org/W2270810037","https://openalex.org/W2295227150","https://openalex.org/W2328670182","https://openalex.org/W2411395611","https://openalex.org/W2489724903","https://openalex.org/W2523592271","https://openalex.org/W2606230253","https://openalex.org/W2766784006","https://openalex.org/W2805112149","https://openalex.org/W2932637460","https://openalex.org/W2943416206","https://openalex.org/W2964012416","https://openalex.org/W2980135126","https://openalex.org/W3006118591","https://openalex.org/W3112246037","https://openalex.org/W3136167138","https://openalex.org/W3142759754","https://openalex.org/W4248780163","https://openalex.org/W4283322590","https://openalex.org/W4293733558","https://openalex.org/W4365456974"],"related_works":["https://openalex.org/W3023414123","https://openalex.org/W2564107867","https://openalex.org/W7156075353","https://openalex.org/W3155351927","https://openalex.org/W2113776905","https://openalex.org/W2026315663","https://openalex.org/W2985066609","https://openalex.org/W2417803980","https://openalex.org/W4255830331","https://openalex.org/W7034032245"],"abstract_inverted_index":{"Introduction":[0],"The":[1,70,93,109],"complement":[2,36,134,265],"system":[3],"is":[4,24],"a":[5,25,114,219,224,230,251],"key":[6],"component":[7,37],"of":[8,20,34,51,53,58,72,95,111,123,143,157,173,199,236,238,254,261,290],"the":[9,18,32,49,56,121,141,155,158,169,197,233,259,286],"innate":[10],"immune":[11],"system,":[12],"and":[13,30,44,91,106,147,154,201,263,269],"its":[14],"aberrant":[15],"activation":[16,172,260],"underlies":[17],"pathophysiology":[19],"various":[21],"diseases.":[22],"Zilucoplan":[23,130,166,190,214],"macrocyclic":[26],"peptide":[27],"that":[28,179,248,273],"binds":[29],"inhibits":[31],"cleavage/activation":[33],"human":[35,133],"5":[38],"(C5).":[39],"We":[40],"present":[41],"in":[42,113,170,223,241],"vitro":[43,171],"ex":[45],"vivo":[46],"data":[47,281],"on":[48,125],"mechanism":[50],"action":[52,237,255],"zilucoplan":[54,73,99,112,124,239,249],"for":[55,77,232],"inhibition":[57],"C5":[59,65,79,135,144,149,152,174,212,221,262],"activation,":[60],"including":[61,76,267],"two":[62],"clinically":[63,287],"relevant":[64,284],"polymorphisms":[66],"at":[67,177],"R885.":[68],"Methods":[69],"interaction":[71],"with":[74,136,196],"C5,":[75],"clinical":[78,175,242,270],"R885":[80,178,271],"variants,":[81],"was":[82,100,118,191],"investigated":[83,101],"using":[84],"surface":[85],"plasmon":[86],"resonance":[87],"(SPR),":[88],"hemolysis":[89,107,207],"assays,":[90],"ELISA.":[92],"interference":[94],"C5b6":[96,200],"formation":[97,198],"by":[98,102,120,151,209],"native":[103],"gel":[104],"analysis":[105],"assay.":[108],"permeability":[110,217],"reconstituted":[115,225],"basement":[116,226],"membrane":[117,160,227],"assessed":[119],"partition":[122],"Matrigel-coated":[126],"transwell":[127],"chambers.":[128],"Results":[129],"specifically":[131],"bound":[132],"high":[137],"affinity,":[138],"competitively":[139],"inhibited":[140],"binding":[142],"to":[145,184,187,194,256,277,285],"C3b,":[146],"blocked":[148],"cleavage":[150],"convertases":[153],"assembly":[156],"cytolytic":[159],"attack":[161],"complex":[162],"(MAC,":[163],"or":[164],"C5b9).":[165],"fully":[167],"prevented":[168],"variants":[176,272],"have":[180],"been":[181],"previously":[182],"reported":[183],"respond":[185,276],"poorly":[186],"eculizumab":[188,278],"treatment.":[189,279],"further":[192],"demonstrated":[193,215,288],"interfere":[195],"inhibit":[202,258],"red":[203],"blood":[204],"cell":[205],"(RBC)":[206],"induced":[208],"plasmin-mediated":[210],"non-canonical":[211],"activation.":[213],"greater":[216],"than":[218],"monoclonal":[220],"antibody":[222],"model,":[228],"providing":[229],"rationale":[231],"rapid":[234],"onset":[235],"observed":[240],"studies.":[243],"Conclusion":[244],"Our":[245],"findings":[246],"demonstrate":[247],"uses":[250],"dual":[252],"mode":[253],"potently":[257],"terminal":[264],"pathway":[266],"wild-type":[268],"do":[274],"not":[275],"These":[280],"may":[282],"be":[283],"benefits":[289],"zilucoplan.":[291]},"counts_by_year":[{"year":2026,"cited_by_count":17},{"year":2025,"cited_by_count":19},{"year":2024,"cited_by_count":15},{"year":2023,"cited_by_count":1}],"updated_date":"2026-10-29T09:56:32.521200","created_date":"2023-08-10T00:00:00"}